A Multicenter, Phase 1, Open-Label, Dose Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Trial Profile

A Multicenter, Phase 1, Open-Label, Dose Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs ABBV 085 (Primary) ; Gemcitabine; Nivolumab; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 15 Nov 2017 Planned End Date changed from 25 Jun 2020 to 28 Dec 2018.
    • 15 Nov 2017 Planned primary completion date changed from 24 Dec 2018 to 29 Jun 2018.
    • 25 Aug 2017 Planned number of patients changed from 208 to 220.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top